The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Expert Discusses Promising Agents in Field of MCL

Andre Goy, MD
Published Online:2:12 PM, Wed March 13, 2019


Andre Goy, MD, chief in the division of lymphoma, chairman and director at John Theurer Cancer Center, discusses the agents he finds promising for the treatment of patients with mantle cell lymphoma (MCL).

BTK inhibitors such as rituximab (Rituxan) have been impressive in the salvage setting, according to Goy. Triplet combinations with venetoclax and ibrutinib in this setting also look like they will move to the frontline for treatment of patients with MCL.

In addition, data for rituximab, bendamustine, and cytarabine (R-BAC) appear impressive in the frontline even when the dose of cytarabine is adjusted in elderly patients. Goy also highlights the importance of doing full pathology, as well as checking for the ECOG status and p53 status.

See more from this interview on MCL here.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.